Fermentalg Reports EUR7.4 Million Revenue in H1 2026

Fermentalg, based in Libourne, announces unaudited revenue of EUR7.4 million for the first half of 2026. This figure nearly matches the EUR7.6 million seen in the same period in 2025, despite significant changes in revenue structure. Notably, sales of ΩRIGINSTM lipids in high-value segments, such as dietary supplements and infant nutrition, grew by nearly 20%, nearing EUR7 million.

The company also marked a strategic reduction in aquaculture sales, which dropped by 85% compared to the first half of 2025. However, rising fish oil prices have recently revived this sector's opportunities. Additionally, Fermentalg initiated new biosolutions sales, including the EPA/DHA ΩRIGINSTM and Galdieria BlueTM natural dye.

The inaugural order of Galdieria BlueTM highlights Fermentalg's expansion into natural dyes, supported by positive FDA and EFSA endorsements and industrial collaboration for large-scale production. Fermentalg is poised for considerable growth, aiming for EUR20 million in annual revenue by year's end, driven by rising demand for sustainable biosolutions.